Overview
Prostate carcinoma is a significant malignancy affecting men, characterized by abnormal cell growth originating in the prostate gland. It often presents asymptomatically in early stages but can progress to cause urinary symptoms and metastasis if untreated 5.Diagnosis
Digital rectal examination (DRE) to assess prostate size and irregularities 5.
Prostate-specific antigen (PSA) blood test for screening 5.
Transrectal ultrasound (TRUS) biopsy for definitive diagnosis 5.
Gleason grading system to assess tumor aggressiveness based on biopsy findings 5.
Staging using TNM classification to determine extent of disease 5.Management
Surgery: Radical prostatectomy for localized disease 13.
Radiation Therapy: External beam radiation therapy or brachytherapy for localized and locally advanced disease 5.
Hormonal Therapy: Androgen deprivation therapy (e.g., GnRH agonists) for advanced or metastatic disease 5.
Active Surveillance: For low-risk patients to monitor disease progression without immediate intervention 5.
Systemic Therapy: Chemotherapy (e.g., docetaxel) for metastatic castration-resistant prostate cancer 5.Special Populations
Elderly: Consider comorbidities and life expectancy when choosing treatment; active surveillance may be appropriate 5.
Comorbidities: Tailor treatment based on coexisting conditions; hormonal therapy may be preferred in patients with cardiovascular risks 5.Key Recommendations
Utilize PSA screening and DRE for early detection of prostate carcinoma 5 (Evidence: Strong).
Employ Gleason grading and TNM staging to guide treatment decisions 5 (Evidence: Strong).
Consider active surveillance for low-risk prostate cancer patients to avoid overtreatment 5 (Evidence: Moderate).
Integrate hormonal therapy as a cornerstone for managing advanced or metastatic disease 5 (Evidence: Strong).
Evaluate patient-specific factors such as age and comorbidities to tailor surgical or radiation approaches 5 (Evidence: Moderate).References
1 Xiao K, Ma Y, Luo Z, Li H, Jin T. Network meta-analysis of the treatment safety and efficacy of different energy systems in prostate vaporization. Lasers in medical science 2023. link
2 Lin L, Li P, Liu X, Xie X, Liu L, Singh AK et al.. Systematic review and meta-analysis of candidate gene association studies of benign prostate hyperplasia. Systematic reviews 2022. link
3 Tokas T, Ortner G, Peteinaris A, Somani BK, Herrmann T, Nagele U et al.. Simulation training in transurethral resection/laser vaporization of the prostate; evidence from a systematic review by the European Section of Uro-Technology. World journal of urology 2022. link
4 Taratkin M, Azilgareeva C, Cacciamani GE, Enikeev D. Thulium fiber laser in urology: physics made simple. Current opinion in urology 2022. link
5 Cannarella R, Condorelli RA, Barbagallo F, La Vignera S, Calogero AE. Endocrinology of the Aging Prostate: Current Concepts. Frontiers in endocrinology 2021. link
6 Zhang Y, Shamie N, Daneshmand S. Assessment of Urologists' Knowledge of Intraoperative Floppy Iris Syndrome. Urology 2016. link
7 Gross AJ, Herrmann TR. History of lasers. World journal of urology 2007. link